{
    "Clinical Trial ID": "NCT00455533",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ixabepilone",
        "  ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)",
        "INTERVENTION 2: ",
        "  Paclitaxel",
        "  paclitaxel 80 mg/m^2 administered IV every week for 12 weeks"
    ],
    "Eligibility": [
        "Inclusion criteria",
        "  Histologically confirmed primary invasive adenocarcinoma of the breast , T2-3, N0-3, M0, with tumor size of  2 cm",
        "  All patients with early stage breast adenocarcinoma may enroll irrespective of receptor status",
        "  No prior treatment for breast cancer excluding therapy for DCIS",
        "  Karnofsky performance status of 80 - 100",
        "  left ventricular ejection fraction (LVEF)  50% by echocardiogram or multiple gated acquisition (MUGA)",
        "  Adequate hematologic, hepatic and renal function",
        "  Exclusion Criteria",
        "  women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable method to avoid pregnancy during and up to 8 weeks after the last dose of the investigational drug",
        "  Women who are pregnant or breastfeeding",
        "  Inflammatory or metastatic breast cancer",
        "  Unfit for breast and/or axillary surgery",
        "  Evidence of baseline sensory or motor neuropathy",
        "  Significant history of cardiovascular disease, serious intercurrent illness or infections including known human immu immunodeficiency virus (HIV) infection",
        "  History of prior anthracycline therapy Allergies to any study medication or Cremophor\u00ae EL"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Percentage of Participants Achieving Pathologic Complete Response (pCR)",
        "  The pCR was defined as no histologic evidence of residual invasive adenocarcinoma in the breast and axillary lymph nodes, with or without the presence of ductal carcinoma in situ (DCIS) in the breast.",
        "  Time frame: at surgery (performed 4-6 weeks after the last dose of 12 weeks of therapy)",
        "Results 1: ",
        "  Arm/Group Title: Ixabepilone",
        "  Arm/Group Description: ixabepilone 40 mg/m^2 administered intravenously (IV) over 3 hours, every 3 weeks for 4 cycles (12 weeks)",
        "  Overall Number of Participants Analyzed: 148",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  24.3        (18.6 to 30.8)",
        "Results 2: ",
        "  Arm/Group Title: Paclitaxel",
        "  Arm/Group Description: paclitaxel 80 mg/m^2 administered IV every week for 12 weeks",
        "  Overall Number of Participants Analyzed: 147",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  25.2        (19.4 to 31.7)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 17/145 (11.72%)",
        "  ANAEMIA 0/145 (0.00%)",
        "  LEUKOPENIA 2/145 (1.38%)",
        "  NEUTROPENIA 1/145 (0.69%)",
        "  LEUKOCYTOSIS 1/145 (0.69%)",
        "  THROMBOCYTOPENIA 1/145 (0.69%)",
        "  FEBRILE NEUTROPENIA 1/145 (0.69%)",
        "  THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%)",
        "  CARDIAC FAILURE 1/145 (0.69%)",
        "  ATRIAL FIBRILLATION 1/145 (0.69%)",
        "Adverse Events 2:",
        "  Total: 11/144 (7.64%)",
        "  ANAEMIA 1/144 (0.69%)",
        "  LEUKOPENIA 0/144 (0.00%)",
        "  NEUTROPENIA 0/144 (0.00%)",
        "  LEUKOCYTOSIS 0/144 (0.00%)",
        "  THROMBOCYTOPENIA 0/144 (0.00%)",
        "  FEBRILE NEUTROPENIA 1/144 (0.69%)",
        "  THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%)",
        "  DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%)",
        "  CARDIAC FAILURE 0/144 (0.00%)",
        "  ATRIAL FIBRILLATION 0/144 (0.00%)"
    ]
}